3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
5
Withdrawn
1
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
8
Rhabdomyosarcoma
4
Triple Negative Breast Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Rhabdomyosarcoma, Embryonal
2
Rhabdomyosarcoma, Alveolar
2
Vinorelbine
1
Uterine Cervical Neoplasms
1
Sarcoma, Ewing
1
Sarcoma
1
Neoplasms
1
Neoplasm Metastasis
1
HR+HER2- Breast Cancer
1
Adenocarcinoma
1
Interventions
pembrolizumab
10
Cisplatin
8
Radiotherapy
6
Magnetic Resonance Spectroscopy
6
Carboplatin
6
Specimen Handling
5
Paclitaxel
5
Brachytherapy
5
Fluorodeoxyglucose F18
4
dostarlimab
3
atezolizumab
3
Trastuzumab
3
Radiation
3
Platinum
3
Nivolumab
3
Human Papillomavirus DNA Tests
3
Docetaxel
3
Colposcopy
3
1,2-diaminocyclohexaneplatinum II citrate
3
zimberelimab
2
tislelizumab
2
spartalizumab
2
olaparib
2
human papillomavirus vaccine, L1 type 16, 18
2
durvalumab
2
Vaccines
2
Surveys and Questionnaires
2
Standard of Care
2
Robotic Surgical Procedures
2
Radiotherapy, Intensity-Modulated
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Uterine Cervical Neoplasms
×
Vinorelbine
×
Clear all
NCT06459180
2026-05-27
TroFuse-020
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
686 enrolled